- Home
- AQMS vs VRAX Comparison
AQMS vs VRAX Comparison
Compare AQMS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- VRAX
- Stock Information
- Founded
- AQMS 2014
- VRAX 2013
- Country
- AQMS United States
- VRAX United Kingdom
- Employees
- AQMS N/A
- VRAX N/A
- Industry
- AQMS Metal Fabrications
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AQMS Industrials
- VRAX Health Care
- Exchange
- AQMS Nasdaq
- VRAX Nasdaq
- Market Cap
- AQMS 5.2M
- VRAX 4.4M
- IPO Year
- AQMS 2015
- VRAX 2022
- Fundamental
- Price
- AQMS $3.87
- VRAX $0.79
- Analyst Decision
- AQMS Strong Buy
- VRAX Strong Buy
- Analyst Count
- AQMS 3
- VRAX 1
- Target Price
- AQMS $210.00
- VRAX $3.00
- AVG Volume (30 Days)
- AQMS 113.4K
- VRAX 190.5K
- Earning Date
- AQMS 08-13-2025
- VRAX 01-01-0001
- Dividend Yield
- AQMS N/A
- VRAX N/A
- EPS Growth
- AQMS N/A
- VRAX N/A
- EPS
- AQMS N/A
- VRAX N/A
- Revenue
- AQMS N/A
- VRAX $6,331.00
- Revenue This Year
- AQMS N/A
- VRAX $217,274.83
- Revenue Next Year
- AQMS $550.00
- VRAX N/A
- P/E Ratio
- AQMS N/A
- VRAX N/A
- Revenue Growth
- AQMS N/A
- VRAX N/A
- 52 Week Low
- AQMS $3.40
- VRAX $0.74
- 52 Week High
- AQMS $54.00
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- AQMS 31.41
- VRAX 38.81
- Support Level
- AQMS $3.40
- VRAX $0.75
- Resistance Level
- AQMS $4.53
- VRAX $0.90
- Average True Range (ATR)
- AQMS 0.55
- VRAX 0.10
- MACD
- AQMS -0.07
- VRAX -0.02
- Stochastic Oscillator
- AQMS 4.81
- VRAX 8.97
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).